Southwest Oncology Group: two decades of experience in non-small cell lung cancer.
Publication/Presentation Date
4-1-2005
Abstract
Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
Volume
32
Issue
2 Suppl 3
First Page
119
Last Page
121
ISSN
0093-7754
Published In/Presented At
Turrisi, A. T., Crowley, J., Albain, K., Gaspar, L., & Gandara, D. (2005). Southwest Oncology Group: two decades of experience in non-small cell lung cancer. Seminars in oncology, 32(2 Suppl 3), S119–S121. https://doi.org/10.1053/j.seminoncol.2005.03.022
Disciplines
Medicine and Health Sciences
PubMedID
16015548
Department(s)
Department of Medicine
Document Type
Article